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Endometriosis, deﬁned as the presence of endometrial tissue outside the uterus, is a common gynecological disease with poorly
understood pathogenesis. MicroRNAs are members of a class of small noncoding RNA molecules that have a critical role in
posttranscriptional regulation of gene expression by repression of target mRNAs translation. We assessed diﬀerentially expressed
microRNAsinectopicendometriumcomparedwitheutopicendometriumin3patientsthroughmicroarrayanalysis.Weidentiﬁed
50 microRNAs diﬀerentially expressed and the diﬀerential expression of ﬁve microRNAs was validated by real-time RT-PCR in
other 13 patients. We identiﬁed in silico their predicted targets, several of which match the genes that have been identiﬁed to be
diﬀerentially expressed in ectopic versus eutopic endometrium in studies of gene expression. A functional analysis of the predicted
targets indicates that several of these are involved in molecular pathways implicated in endometriosis, thus strengthening the
hypothesis of the role of microRNAs in this pathology.
1.Introduction
Endometriosis, deﬁned as the growth of endometrial tissue
outside the uterine cavity, is a common gynecological
disease often resulting in chronic pelvic pain and infertility.
The pathogenesis of endometriosis is likely multifactorial
and several hypotheses have been suggested to explain the
presence of ectopic endometrial tissue and stroma, such
as retrograde menstrual reﬂux [1], immune system defects
[2–10], and ectopic presence of endometrial stem cells
originating the disease [11]. In addition, there is a growing
body of evidence indicating the involvement of genetic
factors in the etiology of endometriosis, as it has been
calculated that there is a 6–9-fold increased prevalence of
this pathology among the 1st-degree relatives of women
with endometriosis, compared to the general population
[12–18]. Extensive investigations have been performed to
characterize the diﬀerences between the eutopic and ectopic
endometrium in order to better understand and deﬁne
the molecular basis of the disease and, indeed, several
studies have revealed a distinct pattern of gene expression in
eutopic and ectopic endometrium [19–24]. The diﬀerences
in gene expression reported in these works include genes
encoding proteins involved in cell adhesion, extracellular
matrixremodeling,migration,proliferation,immunesystem
regulation, and inﬂammatory pathways, thus accounting for
the multiple mechanisms hypothesized to be responsible
for the establishment of ectopic endometrial implants,
including the adhesion of endometrial cells to the pelvic
peritoneum, invasion into the mesothelium, and survival
and proliferation of the ectopic endometrial cells.
MicroRNAs (miRNAs), members of a class of small non-
coding RNA molecules, have a critical role in posttranscrip-
tional regulation of gene expression by repression of target
mRNAs translation. Originally identiﬁed in Caenorhabditis
elegans [25], miRNAs have been shown to operate in a wide2 Journal of Biomedicine and Biotechnology
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Figure 1: Diﬀerential expression of miRNAs in ectopic versus eutopic endometrium. The miRNAs selected for independent validation were
among those with wider diﬀerence in expression between eutopic and ectopic endometrium. The diﬀerential expression of the selected
miRNAs in the ectopic versus eutopic tissues was evaluated by real-time RT-PCR. The expression of each miRNA in eutopic tissue was set to
1. (a) hsa-miR-200a, (b) hsa-200b, (c) hsa-miR-200c, (d) hsa-miR-182, and (e) hsa-miR-202.
∗P < .05.
range of species, including humans. Computational predic-
tions indicate that up to 30% of human genes are potential
targets of miRNAs and that miRNAs compose 1%–5% of
animal genomes [26–29]. MiRNA expression is tissue- and
cell-speciﬁc [30–33]. It has been demonstrated that miRNAs
a r ei m p o r t a n ti nd e v e l o p m e n t a lp r o c e s s e sa sw e l la sf o r
other cellular activities involving cell growth, diﬀerentiation,
and apoptosis. Moreover, several genes encoding miRNAs
have been located at chromosomal fragile sites or regions
of cytogenetic abnormalities associated with cancer and
otherdisorders. Interestingly, miRNAsalteredexpression has
been associated with tumorigenesis, and several studies have
described diﬀerential expression of miRNAs in neoplastic
versus normal tissue [34–38].Journal of Biomedicine and Biotechnology 3
RBM9
C1QTNF8
PNRC1
DDIT4
CAV2
CAV1
HSPA13
PRLR
FOLR1
KAT2B
NCOA2
NCOA3 MED14
MED1 ATAD2
LEP
CBX1
DNMT1
DNMT3B
DNMT3A DAB2IP
EED
EZH2
RBBP7
SIRT1
AEBP2
PHF1
THRA (includes EG: 7067)
TMOD1
NOTCH3
NCOA4
DUSP9
CREB1
ESR1
CCND1
Enzyme
Growth factor
Kinase
Peptidase
Phosphatase
Transcription regulator
Transmembrane receptor
Transporter
Unknown
Relations
Relations
Genes involved in endometriosis
Figure 2: Functional analysis of all the predicted targets of the diﬀerentially expressed miRNAs. Graphical representation of network #2
obtained by IPA analysis. Genes are represented as nodes, and the biological relationship between two nodes is represented as a line. Every
line is supported by at least one reference in literature. Highlighted, the genes involved in endometriosis according to IPA knowledge base.
Our study is aimed to investigate the diﬀerential expres-
sion of miRNAs in endometriosis by direct comparison
between paired ectopic and eutopic endometrium samples.
Once we identiﬁed the diﬀerentially expressed miRNAs, we
validated 5 of them by an independent technique. Then, we
identiﬁed in silico the predicted molecular targets of the dif-
ferentially expressed miRNAs and we used a bioinformatics
tool to investigate the molecular pathways in which these
targets could be involved.
2.MaterialsandMethods
2.1.TissueCollection. Subjects(n=16)scheduledforsurgery
for chronic pelvic pain or infertility at the University
of Piemonte Orientale-aﬃliated “Maggiore della Carit` a”
Hospitalwererecruitedtoparticipateinthisstudy.Thestudy
wasapprovedbythe“MaggioredellaCarit` a”Hospital’sInsti-
tutional Review Board and informed consent was obtained
from all participants. None of the authors have any conﬂict4 Journal of Biomedicine and Biotechnology
Table 1: Diﬀerentially expressed miRNAs in ectopic versus eutopic endometrium. List of diﬀerentially expressed miRNAs whose expression
value in ectopic endometrium was at least twofold higher or lower than in eutopic endometrium P< .01.
Name EU EC P-value
hsa-miR-1 36.29 2,090.27 .00E+00
hsa-miR-100 7,517.73 18,712.43 .00E+00
hsa-miR-101 341.51 2,348.69 .00E+00
hsa-miR-106a 3,264.74 1,510.10 1.11E−16
hsa-miR-106b 2,996.55 1,414.14 .00E+00
hsa-miR-126 10,373.88 22,435.79 .00E+00
hsa-miR-130a 1,634.84 5,145.94 .00E+00
hsa-miR-130b 673.04 249.86 .00E+00
hsa-miR-132 3,699.14 1,261.33 .00E+00
hsa-miR-143 8,104.26 21,764.97 .00E+00
hsa-miR-145 10,992.36 27,550.33 .00E+00
hsa-miR-148a 2,623.73 6,507.58 .00E+00
hsa-miR-150 1,621.96 4,503.15 .00E+00
hsa-miR-17-5p 4,517.66 2,059.32 .00E+00
hsa-miR-182 1,998.92 230.69 .00E+00
hsa-miR-183 410.83 41.02 .00E+00
hsa-miR-186 56.69 246.79 1.21E−14
hsa-miR-196b 380.45 14.13 .00E+00
hsa-miR-199a 4,481.27 12,618.11 .00E+00
hsa-miR-200a 582.95 33.22 .00E+00
hsa-miR-200b 17,643.11 675.98 .00E+00
hsa-miR-200c 25,249.55 1,391.63 .00E+00
hsa-miR-202 49.64 471.06 2.27E−13
hsa-miR-20a 5,278.72 2,534.21 9.05E−14
hsa-miR-221 5,368.05 10,915.55 .00E+00
hsa-miR-25 12,878.14 6,328.31 1.06E−14
hsa-miR-28 1,465.55 4,589.04 .00E+00
hsa-miR-299-5p 202.34 452.17 5.18E−13
hsa-miR-29b 248.51 4,963.66 .00E+00
hsa-miR-29c 295.40 10,562.63 .00E+00
hsa-miR-30e-3p 299.19 1,003.48 1.50E−14
hsa-miR-30e-5p 58.94 428.59 .00E+00
hsa-miR-34a 337.65 861.73 .00E+00
hsa-miR-365 264.57 2,071.70 .00E+00
hsa-miR-368 297.52 1,882.43 .00E+00
hsa-miR-375 1,329.85 13.62 .00E+00
hsa-miR-376a 64.20 522.49 .00E+00
hsa-miR-379 175.21 601.12 7.19E−13
hsa-miR-411 62.72 215.67 5.92E−16
hsa-miR-425-5p 961.30 329.99 .00E+00
hsa-miR-486 2,824.50 956.89 .00E+00
hsa-miR-493-5p 64.60 355.15 7.22E−12
hsa-miR-503 2,084.95 465.94 .00E+00
hsa-miR-638 29,531.60 11,202.65 .00E+00
hsa-miR-663 4,654.42 1,943.14 4.44E−15
hsa-miR-671 2,052.70 955.73 .00E+00
hsa-miR-768-3p 5,841.89 2,901.78 2.81E−06
hsa-miR-768-5p 5,321.54 2,456,43 .00E+00
hsa-miR-93 2,614.63 629.20 .00E+00
hsa-miR-99a 6,766.02 18,369.57 .00E+00Journal of Biomedicine and Biotechnology 5
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Figure 3: Functional analysis of the predicted targets of miR-182, miR-200a, miR-200b, miR-200c, and miR-202 identiﬁed by Pictar and
Targetscan: graphical representation of one of the network (P-value = 10E−37, focus molecules = 35) identiﬁed by IPA analysis of the
predicted targets of the miRNAs whose diﬀerential expression in eutopic and ectopic endometrium was validated by real-time RT-PCR.
Highlighted are the genes involved in endometriosis according to IPA knowledge base.
of interest with the study. Surgery was scheduled 6 to 12
days after the onset of menses. No patients were receiving
hormone therapy at the time of the study or in the previous
threemonths.Thepatientsrangedinagefrom24to48years,
withanaverageof36years.Endometriomaswereremovedat
laparoscopy by excision of the entire cyst wall by stripping
technique, preserving normal ovarian tissue. Hysteroscopy
with directed biopsies, performed to obtain a sample of
eutopic endometrium from the same patient, were carried
out using a 4mm Bettocchi Hysteroscope System with a6 Journal of Biomedicine and Biotechnology
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Figure 4: Functional analysis of the predicted targets of miR-182, miR-200a, miR-200b, miR-200c, and miR-202 identiﬁed by Argonaute2:
graphical representation of the network identiﬁed by IPA analysis of the miRNAs and their predicted targets using the database generated by
Argonaute2 algorithm (P-value = 10E−14, focus molecules = 4).
5Fr operative channel (Karl Stortz GmbH & Co., Tuttlingen,
Germany). Laparoscopy and hysteroscopy procedures were
performed during the same surgical intervention. Freshly
recovered tissues were rinsed in saline solution and divided
in two parts. One half of the tissue was immediately snap-
frozen and kept in liquid nitrogen for further processing,
while the other was sent to the pathology laboratory. The
endometriomas of 9 patients were classiﬁed as moderate,
while 7 were classiﬁed as severe according to the ASRM
guidelines [39].
2.2. RNA Isolation. Total RNA was extracted from tissues
with the miRNeasy kit (Qiagen, Valencia, CA, USA) accord-
ing to the manufacturer’s protocol and quantiﬁed by Quant-
iT RNA Assay Kit with Qubit Fluorometer (Invitrogen,
Carlsbad, CA, USA).
2.3. MicroRNA Microarray Assay and Analysis. Microarray
assay was performed using a service provider (LC Sciences).
Ten μg of total RNA from eutopic and ectopic endometrium
obtained from three patients were size fractionated using a
YM-100Microconcentrifugalﬁlter(Millipore)andthesmall
RNAs (<300nt) isolated were 3 -extended with a poly(A) tail
using poly(A) polymerase. An oligonucleotide tag was then
ligated to the poly(A) tail for later ﬂuorescent dye staining;
twodiﬀerenttagswereusedforthetwoRNAsamplesindual-
sampleexperiments.Hybridizationwasperformedovernight
on a μParaﬂo microﬂuidic chip using a microcirculation
pump (Atactic Technologies) [40, 41]. On the microﬂuidic
chip,eachdetectionprobeconsistedofachemicallymodiﬁed
nucleotide coding segment complementary to target 475
mature human miRNA probes (Sanger miRBase sequence
database 9.1) or other RNAs for control and a spacer
segment of polyethylene glycol to extend the coding segment
away from the substrate. The detection probes were made
by in situ synthesis using PGR (photogenerated reagent)
chemistry. The hybridization melting temperatures were
balanced by chemical modiﬁcations of the detection probes.
Hybridization used 100μL 6xSSPE buﬀer (0.90M NaCl,
60mMNa2HPO4,6mMEDTA,pH6.8)containing25%for-
mamide at 34
◦C. After RNA hybridization, tag-conjugating
Cy3 and Cy5 dyes were circulated through the microﬂuidic
chip for dye staining. Fluorescence images were collected
usingalaserscanner(GenePix4000B,MolecularDevice)and
digitized using Array-Pro image analysis software (Media
Cybernetics). Data from miRNA microarray were analyzed
by the service provider ﬁrst subtracting the background
and then normalizing the signals using an LOWESS ﬁlter
(Locally weighted Regression) [42]. The ratio of the two
sets of detected signals (log2 transformed, balanced) and P-
values of the t-test were calculated; diﬀerentially detected
signals were those with less than .01 P-values. Multiple
sample analysis involved normalization, data adjustment, t-
test, and clustering. Normalization was carried out using
a cyclic LOWESS. Data adjustment included data ﬁltering,
Log2 transformation, and normalization. The t-test was
performed between “control” and “test” sample groupsJournal of Biomedicine and Biotechnology 7
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Figure 5: The axon guidance pathway identiﬁed by Pathway-Express analysis. Pathway-Express analysis performed on the predicted targets
of the 50 diﬀerentially expressed miRNAs identiﬁed, among the most signiﬁcant KEGG pathways predicted to be relevant for endometriosis,
the axon guidance pathway. In yellow are the predicted targets of the diﬀerentially expressed miRNAs.
[43]. T-values were calculated for each miRNA, and P-
values were computed from the theoretical t-distribution.
miRNAs with P-values <. 01 were selected for cluster
analysis. The clustering was done using hierarchical method
and was performed with average linkage and Euclidean
distance metric [44] using TIGR MultiExperiment Viewer
(http://www.tm4.org/mev.html).
2.4. Reverse Transcription and Real-Time PCR. Real-time
reverse transcription-polymerase chain reaction (real-time
RT-PCR) was performed to conﬁrm the diﬀerential expres-
sionofselectedmiRNAs,identiﬁedasdiﬀerentiallyexpressed
by miRNA microarray, in paired samples from other 13
patients. TaqMan MicroRNA RT Kit (Applied Biosystems,
FosterCity,CA)wasusedforreversetranscription.Real-time
RT-PCR reactions were carried out with a 7300 Real-Time
PCR System (Applied Biosystems) according to the protocol
provided by the supplier, using the TaqMan Universal PCR
Master Mix No AmpErase UNG and the following TaqMan
MicroRNA Assays: hsa-miR-200a, hsa-miR-200b, hsa-miR-
200c, hsa-miR-182, hsa-miR-202, and U18 as endogenous
control.
Data from real-time RT-PCR experiments are presented
as the mean ± SEM. The variation among groups was
compared by means of nonparametric Wilcoxon and Mann-
Whitney U tests. Statistical signiﬁcance was assumed for P-
values <. 05. Statistical analysis was performed with SPSS for
Windows version 15.0 (SPSS; Chicago, IL).
3. Results and Discussion
3.1. MicroRNAs Diﬀerentially Expressed in Eutopic and
Ectopic Endometrial Tissue. In the present study, we used
miRNA microarray technology to identify the pattern of
miRNAs in paired eutopic/ectopic endometrium from the
same patients, thus avoiding the variables attributable to
heterogeneous genetic background between individuals and
the eﬀects of estrogenic stimulation during diﬀerent phases
of the menstrual cycle. Moreover, we considered the whole
endometrial and endometriotic tissues in order to preserve
the contribution of all the components of the tissues,
including vascular and immune system components and to
avoid potential changes in gene and miRNA expression due
to cell isolation and manipulation.8 Journal of Biomedicine and Biotechnology
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Figure 6: Functional analysis of the diﬀerentially regulated genes common in ovarian and peritoneal endometriosis that are predicted
targets of the 50miRNAs: Graphical representation of the overlap of the networks identiﬁed by IPA with, highlighted are the genes involved
in endometriosis according to IPA knowledge base.
Microarray technology has allowed a global analysis of
all miRNAs diﬀerentially expressed in ectopic versus eutopic
endometrium. The initial analysis of miRNA expression in
ectopic endometrium compared with eutopic endometrium
of three patient samples generated a list of 84miRNAs
signiﬁcantly diﬀerentially expressed (P-values <. 01). The
50miRNAs for which the expression value in ectopic
endometrium was at least twofold higher or lower than in
eutopic endometrium are listed in Table 1.
3.2. Real Time RT-PCR Analysis of miRNA Expression.
In order to conﬁrm the results obtained with miRNA
microarray,theexpressionanalysesof5selectedmiRNAswas
carried out by real-time RT-PCR on specimens from other
13 patients. These 5miRNAs, namely, hsa-miR-200a, hsa-
miR-200b, hsa-miR-200c, hsa-miR-182, and hsa-miR-202,
were selected because their expression resulted to be highly
altered in ectopic endometrium compared with the matched
eutopic tissue. We veriﬁed the diﬀerential expression of theJournal of Biomedicine and Biotechnology 9
Table 2: Molecular networks constituted by the predicted miRNA targets. IPA analysis was performed in order to identify the molecular
pathways and functions to which the predicted targets of the diﬀerentially expressed miRNAs belong. The networks are generated on the
basis of the published literature and ranked by the P-value calculated by Fisher’s exact Test. The biological processes in which the targets are
involved are determined by IPA using the GOstat application P<. 01.
ID Molecules in network P-value Focus
molecules
Top functions
1
ACTR1A, ADM, APP, BICD2,
CABP7, CELSR1, CPSF6, DAG1,
ELAVL1, EPHA2, GCH1, GNA13,
HIRA, HLX, HNRNPH1,
HNRNPM, IFNG, IRF2,
KHDRBS1, LARGE, MAPT,
MTMR3, MTMR4, MYH9,
PCSK2, PLCG1, PTGS2, RASA1,
SBF1, SOCS1, SOCS2, STAT6,
TNPO1, TNPO2, TRIB2
10E−21 35
Cellular Development, Skeletal
and Muscular Disorders,
Organismal Development
2
AEBP2, ATAD2, C1QTNF6,
CAV1, CAV2, CBX1, CCND1,
CREB1, DAB2IP, DDIT4,
DNMT1, DNMT3A, DNMT3B,
DUSP9, EED, ESR1, EZH2,
FOLR1, HSPA13, KAT2B, LEP,
MED1, MED14, NCOA2, NCOA3,
NCOA4, NOTCH3, PHF1,
PNRC1, PRLR, RBBP7, RBM9,
SIRT1, THRA (includes EG:7067),
TMOD1
10E−21 35
Gene Expression, Cellular
Growth and Proliferation,
Developmental Disorder
3
AKAP13, BCL2L11, CCNE2,
CDK6, CDKN1A, CDKN1B,
CTGF, CTSB, CUGBP1, DUSP1,
E2F1, ESRRG, ETS1, FHL2, FLI1,
FOXO1, FOXO3, FOXO4, IGFBP3,
IP6K3, JAG1, KRAS, MCF2,
NR3C1, PRKD3, RB1CC1, SGK1,
SMAD3, SP1, SPHK2, TCF7L2
(includes EG:6934), TGFBR1,
TIMP3, TOPBP1, TSPYL2
10E−21 35
Cellular Growth and
Proliferation, Cellular
Development, Cancer
4
ADAM12, BCL2, CITED2,
EGLN1, FGF9, FRAP1, GATA3,
GNAI2, HIF1A, HSPD1, IGF1R,
IKBKB, ITGA9, JUNB, KPNA1,
KPNB1, MAP2K3, MAP2K5,
MAP3K7, MAP3K7IP2, PIAS3,
PPM1B, PRKCE, PTEN, PTPN1,
RPS6KB1, SKI, SMAD7, SNAI1,
SOCS3, SP2, STAT3, UBR5, WT1,
ZEB1
10E−21 35
Cellular Growth and
Proliferation, Cellular
Movement, Cell Cycle
5
ANP32A, ATP2A2, CD69,
CDK5R1, COL1A1, COL1A2,
CREM, DDR1, DLL4, E2F3,
EGR1, FBXW7, FLT1, HDAC4,
IL2, IL18BP, LPL, NDRG1,
NOTCH1, PHC1, PHC2, POLA1,
PPARA, RANBP2, RB1, RYBP,
SHC1, SP3, SP4, TRAM2
(includes EG:9697), XPO1, YBX1,
YY1, ZBTB10, ZBTB7B
10E−21 35
Organismal Injury and
Abnormalities, Cardiovascular
Disease, Cellular Development10 Journal of Biomedicine and Biotechnology
Table 2: Continued.
ID Molecules in network P-value Focus
molecules Top functions
6
ARNT, BACH1, BCL2L12,
BRCA1, CLOCK, CREBBP,
CYP1B1, DDX5, EP300, EPAS1,
ERBB4, EREG, GABPA,
GADD45A, HBEGF, HOXA13,
HOXB6, LEF1, MAB21L1, MAX,
NCAM1, NFYA, NPAS2, OXTR,
PIN1, PPARG, PPP2CA, PTGER4,
RBBP8 (includes EG:5932),
RUNX1, SDC1, SLC1A2, TGFA,
TRERF1, WNT5A
10E−21 35 Gene Expression, Cancer,
Genetic Disorder
7
ACTB, ARID1A, ARID1B,
ARID4A, ARID4B, BTG2, CLIP1,
DR1, ETS2, EWSR1, GTF2B,
HOXA9, PFN1, RARB, RBL1,
RBL2, SAP30, SAP130, SFPQ,
SIN3A, SMARCA2, SMARCA4,
SMARCB1, SMARCC1,
SMARCC2 (includes EG:6601),
SNIP1, SUMO1, TACC2, TAF4,
TAF5, TAF12, TBP, TDG, TOP1,
XPO6
10E−21 35
Gene Expression, Cellular
Assembly and Organization,
Cellular Compromise
8
ARHGDIA, BTRC, CASP3, CD4,
CDC42, CLTC, CTTN, CXCL12,
DIABLO, ELK1, ELK3, EZR, F3,
FOS, FOSB, GLI3, GSK3B,
HNRNPA1, HNRNPC, IL1A,
ITPR1, JUND, MAP1B, MCL1,
OCRL, PAK1, PGM1, PRKCI,
PRKD1, PTX3, RABEP1, RAC1,
SEMA3A, SRF, STK4
10E−21 35 Cell Death, Cancer, Cellular
Assembly and Organization
9
CD47, CSF1, CSF1R, CSK,
EPHA4, FASLG, FGF1, FN1,
FOXP1, GRB2, IRS2, ITGA5,
ITGA6, ITGA10, ITGA11, ITGAV,
ITGB1, ITGB3, JAK2, KCNA3,
MAP2K1, MAP2K4, MAPK1,
MET, MITF, NFAT5, PDGFB,
PDGFRB, PLXNB1, RAB21,
SERPINE1, TNFRSF1A,
TNFSF11, TRIB1, YES1
10E−21 35
Cellular Growth and
Proliferation, Cell-mediated
Immune Response, Cellular
Movement
10
ACTR3, AR, ARHGEF7, ASAP1,
CRKL, DYRK1A, ESR1, GDI1,
KLF2, LMOD1, LRRK1, MRAS,
NCK1, PFTK1, PLS3, POMT2,
TEAD3, TRIP10, WAS, WEE1,
WIPF1, ZMIZ1
10E−91 9
Cellular Assembly and
Organization, Skeletal and
Muscular System Development
and Function, Cancer
11
AKAP12, AMOTL2, ARL6IP1,
ATM, BRCA1, CDC6, CHEK2,
E2F1, FKBP3, HS3ST1, LATS2,
LBR, MBNL2, MTDH, PPM1D,
PPP1R13B, SCN3B, SH3BP4,
TP53, TRIO, VCAN
10E−71 7 Cancer, Genetic Disorder,
Reproductive System Disease
12
ANK3, CREB5, DEDD, FRK,
GPRC5A, KCNK2, KRT18,
MPZL2, MYCBP2, MYO1B, NRK,
RAB22A, SPAG9, ZNF217
10E−71 3
Cardiovascular Disease,
Cellular Development, Cell
MorphologyJournal of Biomedicine and Biotechnology 11
Table 2: Continued.
ID Molecules in network P-value Focus
molecules Top functions
13
ADAM19, CADM1, CBFA2T3,
CDC42SE1, COL6A3, COL7A1,
DAAM1, ERBB2, FN1, HAS3,
MFAP2, MPHOSPH9, NET1,
PMEPA1, RAP1B, TGFB1, THBS1,
THPO, XYLT1, ZFP36
10E−71 6
C a n c e r ,C e l l u l a rG r o w t ha n d
Proliferation, Dermatological
Diseases and Conditions
14
ATP1B3, CCND1, COL3A1,
COL4A1, COL5A2, CTNNB1,
HOXA1, IGF2R, KLF9, LGALS3,
M6PR, MAP3K10, NANOG,
NPTX1, NRF1, NRIP1, PTPRC,
PTTG1, RB1, SPTBN2, TCF7L2
(includes EG:6934), THRB
(includes EG:7068), TP53
10E−61 7 Organismal Development,
Cancer, Cell Cycle
15
ALDH1A3, COLQ, DUSP10,
EIF4B, GPD2, HSPE1, IL6, IL13,
IL1B, MMD, NR4A3, NUAK1,
PTPN12, RND3, ROBO1,
SEMA3C, SLC7A1, STAC, TNF,
TNFSF10, TUB
10E−61 6
Small Molecule Biochemistry,
Skeletal and Muscular System
Development and Function,
Cell-To-Cell Signaling and
Interaction
16
ACSL3, ASXL1, EGR3, JMJD1C,
PLK2, PTP4A1, RRM2, RRM1
(includes EG:6240), RRM2B,
SEL1L, SFRS3, SLC2A1, SMURF2,
SON, STRN3, TNF, TP53, UBE2B,
ZFP36L1
10E−61 5
Nucleic Acid Metabolism, Small
Molecule Biochemistry, Genetic
Disorder
17
CCND1, CCNT1, CCNT2, CDK9,
CDKN1A, DNAJB9, FBXW11,
GLI1, GLI2, GNAO1, GTF2F2,
HSPA5, HTATSF1, ID2, JAG2,
MDFIC, MXI1, MYCN, NPM1
(includes EG:4869), POLR2A,
POLR2C, RB1, RPS6KA1, RXRA,
SFRS1, SUPT5H, SUPT6H,
TCERG1, TGFB1, TP53, ULK1
10E−62 0 Gene Expression, Cellular
Development, Cell Cycle
18
APBB2, BECN1, CAD, CDKN1A,
CFL1, E2F5, ESR1, FANCA,
FANCC, FGF7, GFI1, GJA1,
GORASP2, HSP90AA1, LIMK1,
MAX, MYC, PCBP2, PERP,
PTBP1, SPTAN1, TERT, TMSB4X,
TP53, XBP1
10E−51 7
Cell Cycle, Connective Tissue
Development and Function,
Cellular Compromise
19
AP3M1, BCL6, CCND1, CREBL2,
ENC1, FOXA1, FTH1, HNF1A,
HNMT, MTA3, MUC4, NCOR1,
NCOR2, NFE2L2, NFYC, NR5A2,
SNX17, SSTR1, TFR2, TFRC,
TMOD2
10E−51 5 Cancer, Gene Expression, Drug
Metabolism
20
ACTB, ACTL6A, CCNT1, CD9,
CTCF, DMAP1, EMD, EPC1,
ESR1, HABP2, HNRNPA1,
HNRNPF, HNRNPK, HSP90AA1,
LEMD3, MKNK2, MORF4L1,
MYC, PCBP1 (includes EG:5093),
SYNE2, TBP, THOC4, TNPO1,
TRRAP, U2AF1, WNT1, WNT2B,
YY1, ZBTB33
10E−51 8 Gene Expression, Cancer,
Reproductive System Disease12 Journal of Biomedicine and Biotechnology
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21
BEX2, CDH1, CDH2, CDH11,
CTNNA2, CTNNB1, CTNND2,
DIO2, ELAVL1, EPHB3, ERBB2,
ESR1, F13A1, HNRNPD, ILF3,
IRS1, JUP, KHSRP, LDB1, LMO2,
NHLH2, PIK3R1, PKD1,
PPP3CA, PTCH1, PTPRF, TCF7L2
(includes EG:6934), TIAL1, TP53,
TSC22D1, ZNF346
10E−41 8
Cell-To-Cell Signaling and
Interaction, Cancer, Cellular
Growth and Proliferation
22
ACIN1, AP2A1, BRD2, COIL,
EIF4A1, EIF4G3, ICMT, LMO7,
MAP7, NME1, PA2G4, PABPC1,
PABPN1, PAIP1, PAIP2, PAPOLG,
PNN, RNGTT, RNPS1, SAP18,
SFRS11, TALDO1, TRA2B,
ZNF143
10E−41 5
RNA Post-Transcriptional
Modiﬁcation, Protein Synthesis,
Gene Expression
23
ADAM9, ADAM10, BMP7, CCL2,
CCL5, CDH1, COL18A1,
CTNNB1, DICER1, EGF, EGFR,
EPS15, ERBB2, ETV1, GRB2,
HGS, IL8, L1CAM, LPAR1, LPP
(includes EG:4026), MAP3K14,
NKRF, RALA, RELA (includes
EG:5970), SHC1, SMAD5, SPG20,
SRC, TBK1, TERT, TJP1,
TMEM55A, TMEM55B, TNF
10E−41 9
Cell-To-Cell Signaling and
Interaction, Tissue
Development, Cancer
24
ALOX15, BZW2, CCL3, CHST2,
DHCR24, FCER2, GAS7, GATA6,
IGHE, IL4, IL8, IL13, MTSS1,
NHLH1, NOS2, NOTCH2,
PDGFC, PHLDA1, PLXNC1,
RIN2, SORT1, ST8SIA4
10E−41 4
Genetic Disorder,
Inﬂammatory Disease,
Respiratory Disease
25
CAND1, CCND2, CDC5L,
CDKN1B, CUL1, CUL2, CUL3,
D N T T ,F B X L 3 ,F B X W 2 ,G P R 3 7 ,
PARK2, PITX2, PLRG1, PMS1,
PRCC, PRPF19, PSMA2, PSMC1,
PSMC5, RAD23B, RBX1 (includes
EG:9978), SFRS2, SKP1, SKP2,
TCEB1, VHL
10E−41 6
Post-Translational
Modiﬁcation, Cancer,
Immunological Disease
26
AMOT, B4GALT5, BTG3, CCL2,
CD40, CHMP2B, CLASP1, ETS1,
F3, FOS, HIVEP1, IKBKB, IL2,
IL6, IL15, JAK1, JUN, MAPK1,
MAPK14, MVP, NEFM, NFKB1,
NFKBIA, PLG, PPP2R1B, RAB32,
RELA (includes EG:5970),
RFWD2 (includes EG:64326),
RGS2, SQSTM1, STAT1, STAT3,
TNF, TYK2, ZBTB11
10E−41 9
Hematological System
Development and Function,
Cell Death, Cell Cycle
27
CCNA2, CCNB1, CCNE1,
CCNE2, CD46, CD59, CDK2,
CDKN1C, E2F4, EPHB2,
FBXO32, HDAC9, HIVEP2,
IGFBP3, KLF4, LATS1, LTC4S,
MYB (includes EG:4602), MYBL2,
NDC80, NUMB, PCNA, PLAU,
POLD1, RALBP1, RBL1, RBL2,
RFC4, RFX1, SCD, SPARC,
SUZ12, TGFB1, TGFB3, TNS3
10E−41 9 Cell Cycle, Cancer, Cellular
Growth and ProliferationJournal of Biomedicine and Biotechnology 13
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28
ABL1, ADRB2, ATP1A1, ATP1A2,
ATP1B1, BCAR1, BCAR3, BCR,
CBL, CRK, DOCK1, FRAP1, FYN,
GATA2, GRK4, ITGA2B (includes
EG:3674), ITGB3, MAPK9,
MGRN1, NEU2, PIAS1, PIK3R1,
PLSCR1, PRKCD, PTK2,
RAPGEF1, RECK, SP3, SRC,
STAT1, TIMP2, TP73, TP53INP1,
TSG101, VPS28
10E−41 9
Cell Death, Cellular Movement,
Cellular Growth and
Proliferation
29
AKAP11, B2M, BHLHE40,
CALD1, CEBPA, CHI3L1,
COL16A1, EDN1, EDNRB,
EIF1AX, EMP1, HMGA1,
HMGCR, HMGCS1, IDI1,
INSIG1, IPO13, KIT, KITLG, LSS,
MMP2, MMP3, NAMPT, NPPB,
PRKCA, PTPN6, RETN, SCARB1,
SERPINB1, SERPINE1, TGFBR2,
TGIF2, TNC, TNF, UBE2I
10E−41 9 Cancer, Hematological Disease,
Lipid Metabolism
30
ALOX12B, APOE, ATF7IP,
BCAT2, CAMK2A, CAMK2N1,
CCND3, CDKN1B, CHAF1A,
CRYBB2, DPP4, EFNA5, ESR1,
GSTP1, HBE1, IL4, IL13RA1,
IRF4, KCNK10, MBD1, MBD2,
MBD3 (includes EG:53615),
MECP2, MGMT, NR1H3, NR2F2,
PIP5K3, PRLR, PTPN4, PTPRM,
SETDB1, SLCO3A1, TFF2,
TP53BP2, TSC1
10E−41 9
Behavior, Reproductive System
Development and Function,
Neurological Disease
31
ARHGEF6, BNIP2, CASP8,
CHFR, CPD, CS, ELF1, IFNB1,
IL8, IL16, INS, IRF1, JAK2,
LMTK2, NCF2, NFKBIA, NGFR,
PGAM1, PGK1, PLAGL2,
PPP1CC, PPP1R12B, PRL, STAT1,
TNF, TRADD
10E−31 5 Immunological Disease, Cell
Death, Hematological Disease
32
ACHE, AGT, APP, ATP2B1,
BACE1, BIK, BMP2, BTG2,
CCL20, CD40LG, CDH1, CXCL2,
CYCS (includes EG:54205),
EFNA1, EIF4E, EIF4EBP1, GCLC,
ITM2B, JUN, LAMP3, LYN,
MYO6, PDK4, PPARD, PSEN1,
PTGS2, PXN, SMAD1, SMPD2,
SOX9, TNF, TNFAIP2, TNFSF10,
TRPV6, VCL
10E−31 8
Cell Death, Cancer,
Cell-To-Cell Signaling and
Interaction
33
AHR, ANP32B, ATM, BIRC3,
BTG2, CAMK2G, CEBPE, CLU,
ELAVL1, ERCC1, GDF11, H2AFX,
HDAC3, HNRNPD, HNRNPU,
HOXA5, ILF3, NEDD8, NUP153,
RAD50, RARA, RARB, RARG,
TBX3, TERF2, TERF2IP, TIA1,
TIAL1, TINF2, TP53, TPR, XPO1,
XRCC5, XRCC6, YAP1
10E−31 8
Cell Cycle, DNA Replication,
Recombination, and Repair,
Cell Death14 Journal of Biomedicine and Biotechnology
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34
ADH5 (includes EG:128), ASH2L,
ATP6V0C, C16ORF53, CHRNA5,
CSNK2A1, CSNK2B, DPY30,
EDA, ETV4, HCFC1, HDAC1,
HIST2H4A, MIER1, MLL3,
MLL4, MRC2, NCOA6, OGT
(includes EG:8473), PAXIP1,
PKNOX1, PLAU, PLAUR,
POU2F1, RBBP5, SIN3A, SP1,
SP3, SSRP1, SUB1, SUPT16H,
TEAD1, TRIM63, WDR5,
ZBTB7A
10E−31 8
Gene Expression, Cell
Morphology, Reproductive
System Development and
Function
35
APLN, BID, CASP2, CFLAR,
CXCL13, CYCS (includes
EG:54205), DIABLO, EIF2S1,
EIF4B, EIF4E, EIF4EBP1, EIF4G1,
IL21, IL1RN, INHA, INHBA,
INHBB, JAK1, LEFTY1, MCL1,
NFKB2, P4HA1, PPP1R15A
(includes EG:23645), PRDM1,
SATB1, SERPINB2, SOCS1,
SOCS3, SUV39H1, TAL1, TLR4,
TNF, TNFSF10, USF1, USF2
10E−31 8 Protein Synthesis, Cancer, Cell
Death
36
CEBPB, CSF1, CSF3, EGFR, FGA,
GAB1, GRB2, IL6, IL1A, IL6ST,
IRS1, JAK1, KIF5B, LIFR, LMO4,
LPAR2, MAP2, MED28, NF2,
NFKB1, OSM, OSMR, PIK3C2B,
PLG, POU2F1, POU2F2, PRL,
PTGS2, PTPN11, RNASE1,
RNASE2, SKAP2, STAT3, TLR9,
VIP
10E−31 8
Cellular Development, Cellular
Growth and Proliferation,
Cancer
37
AOF2, BAZ1A, BAZ1B,
CACNA1C, CDYL, CHRAC1,
CTBP1, CTBP2, EHMT1,
E H M T 2 ,G A T A 4 ,H A N D 1 ,
HAND2, HDAC2, HMG20B,
KCNJ3, MEF2C, MYOCD,
PDS5A, PHF21A, POLE3, RAD21,
RBBP4, RCOR1, RREB1, SCN5A,
SFRP1, SMARCA1, SMARCA5,
SMC3, SMC1A, STAG1, STAG2,
WIZ, ZEB2
10E−31 8
Cell Cycle, DNA Replication,
Recombination, and Repair,
Gene Expression
38
AKAP1, API5, ARHGEF12, CFTR,
COL18A1, F2, F2R, FGF2, FGFR1,
IL1B, IQGAP2, MPRIP,
PPP1R12A, PRKAR2B, PRKG1,
PTGER3, RHOA, SH3GLB1,
SH3GLB2 (includes EG:56904),
S L C 9 A 3 R 1 ,S R C ,S T X 1 A ,V C P
10E−31 3
Cellular Assembly and
Organization, Cell
Morphology, Cancer
39
ACVR1, ACVR1B, ACVR2A,
ANTXR1, APC, ASAP2, BCAP31,
BIN1, BMP2, BMP6, BMP7,
BMPR2, BMPR1A, CANX,
COL18A1, CTNNB1, DCTN1,
EFNB2, ERBB2, F10, ICAM1, ID1,
ITGB2, MAPRE1, NOG, NRP1,
PLP2, SEC23A, TGFB1, TLN1,
TNFRSF21
10E−31 6
Cell Signaling, Cellular
Development, Connective
Tissue Development and
FunctionJournal of Biomedicine and Biotechnology 15
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40
ARCN1, BRCA2, BRIP1, COPB1,
COPG, CYLD, EXO1, HERC2,
KPNA2, KPNB1, MAD2L2,
MLH1, MMS19, MSH6,
PIK3C2A, PMS1, PMS2, PSD2,
PSMC1, RANBP9, REV1, REV3L,
RFC2, RUFY1, SACM1L, SBF2,
SSB (includes EG:6741), TMED9,
UBA52, UBR5, USP5
10E−21 5
DNA Replication,
Recombination, and Repair,
Cancer, Gastrointestinal
Disease
41
CCNB1, CD44, EGFR, EIF3A,
ERBB2, ERRFI1, GAB1, IL6ST,
JARID1B, KRT7, MYBL2, MYO10,
NEDD9, PARP1, PIK3CA,
PIK3CD, PIK3R1, PIK3R2,
RAB31, SMAD2, SOLH, SOX4,
TGFB1, TGIF1, TGOLN2
(includes EG:10618), TNF
10E−21 3
Cell Cycle, Cellular Growth and
Proliferation, Carbohydrate
Metabolism
42
ADCYAP1, AMPD3 (includes
EG:272), CCL3, CCL4, CCL5,
CD40, CD40LG, CSF3, CXCL10,
DUSP1, DUSP6, FURIN, IER2,
IL3, IL17A (includes EG:3605),
IL1B, ITGAM, MAP2K6, MAPK3,
MAPK14, MMP9, NAMPT,
NFKB2, NGF, NR4A2, NSMAF,
P2RX7, PLD1, PLG, PTGFR,
SERPINB2, TOB1, TRAF3,
TSC22D3, VEGFA
10E−21 6
Cellular Movement,
Hematological System
Development and Function,
Immune Cell Traﬃcking
43
ATM, ATR (includes EG:545),
C10ORF119, CDC6, CDC37,
CDC25A, CDC25B, CHEK1,
CHEK2, CSNK1A1, E2F1, FAS,
GRB10, MAP3K11, MAP3K5
(includes EG:4217), MCM2,
MCM3, MCM4, MCM7, MDM4,
PLK1, PPP2R3A (includes
EG:5523), PPP5C, RAD17, RAF1,
SNAP23, SSH2, STX4, STX6,
STX16, TP53, VAMP2, VAMP3,
VIM, YWHAB
10E−21 6
DNA Replication,
Recombination, and Repair,
Cancer, Cell Cycle
44
BAK1, BAX, BCL2, BCL2L1, BID,
BMF, BSG, CAV1, CAV3, CDC2,
CDK2, CIT, CYCS (includes
EG:54205), DLG4, ECT2, GIT1,
GRIN2A, HINT1, HTT, IGFBP5,
KIF14, KIF23, KRAS, LRP1,
MEOX2, NCL, NCSTN, NT5C3,
PLK1, PRC1, PSEN1, PSEN2,
RACGAP1, TP53, VDAC2
10E−2 15 Cell Death, Cell Cycle, Cancer
45
ASCL2, ASF1A, ATXN7, CCNH,
CDK7, CRIP2, CSPG4, DKK1,
ENO3, ERCC2, ERCC3, ESRRA,
GK, GPR64, GTF2H1, GTF2H2,
HMGN1, MLL2, MNAT1, NR2C2,
NT5E, PPARGC1A, RBBP5, SAFB,
SMAD6, TAF1, TAF2, TAF4,
TAF8, TAF9, TAF11, TAF15, TFF1,
TUBB, UTX
10E−21 5
Gene Expression, DNA
Replication, Recombination,
and Repair, Dermatological
Diseases and Conditions16 Journal of Biomedicine and Biotechnology
Table 2: Continued.
ID Molecules in network P-value Focus
molecules Top functions
46
ADAMTS5, BAX, BCL2, BCL2L1,
BRCA1, CASP3, CCL3, CCL4,
CD226, CD244, CSF2, FLNB,
GP9, GP1BA, IL8, IL15, IL18,
IL18R1, KLRK1, LCP2, MMP1
(includes EG:4312), MNT,
MOAP1, NCR1, PDIA3, RAB9A,
SELL, SOD2, TERT, TP63,
VDAC1, XRCC6, YWHAE,
YWHAQ (includes EG:10971),
YWHAZ
10E−21 5
Cell-to-Cell Signaling and
Interaction, Hematological
System Development and
Function, Cell Death
47
ABCA1, AKT1, APOA1,
CCDC88A, CCL2, CCL5,
COL2A1, CSH1, CUL5, FKBP1A,
FLOT1, IGF1, IL8, IL13, IL1B,
IL1RN, ILK, INS, LOX, MMP7,
PDE4D, PDPK1, PGF, RNF4,
RYR1 (includes EG:6261),
SLC2A4, STK38L (includes
EG:23012), TNF, TRPS1
10E−21 3
Cell-mediated Immune
Response, Cellular Movement,
Lipid Metabolism
48 EIF2C1, EIF2C2, TNRC6A 10E−23 Infection Mechanism, Cancer,
Respiratory Disease
49 DMD, DTNA, DTNB 10E−23
Cellular Assembly and
Organization, Nervous System
Development and Function,
Skeletal and Muscular System
Development and Function
selected miRNAs in the ectopic tissue by setting as 1 the
expression of eutopic miRNAs. The results obtained by real-
timeRT-PCRareinaccordancewiththoseobtainedfromthe
microarray. Indeed, these miRNAs showed signiﬁcant diﬀer-
ential expression (P-values < .05) in eutopic versus ectopic
tissue:hsa-miR-200a,hsa-miR-200b,hsa-miR-200c,andhsa-
miR-182 levels in ectopic endometrium were reduced up to
95% (Figures 1(a)–1(d)), while hsa-miR-202 expression in
ectopic endometrium was increased up to 60 folds compared
to eutopic endometrium (Figure 1(e)) .T h ea n a l y s i so fd a t a
according to the severity of the endometrioma, by means of
nonparametric Wilcoxon and Mann-Whitney U tests, failed
to reveal any signiﬁcant diﬀerences in miRNA expression
levels, although this may be ascribable to the group size.
Further studies increasing the cohort will be necessary to
completely address this issue.
3.3. Identiﬁcation of Predicted miRNA Targets and In Silico
Functional Analysis. The predicted target mRNAs of the
diﬀerentially expressed miRNAs common to two diﬀerent
search algorithms, TARGETSCAN (http://www.targetscan
.org/) and PICTAR-VERT (http://pictar.mdc-berlin.de),
were 3093. The functions of these predicted targets and
the molecular pathways in which they could be involved
were assessed using Ingenuity Pathways Analysis software
(Ingenuity IPA 7.5). The predicted targets were uploaded
in IPA, and the software identiﬁed 49 signiﬁcant molecular
networks to which the predicted targets of the diﬀerentially
expressed miRNAs belong (Table 2). Among the biological
functions reported to be statistically signiﬁcant by IPA there
were functions known to be involved in endometriosis
such as gene expression, cellular growth and proliferation,
cellular development, cellular movement, cell death, cell
cycle, cancer, and reproductive system disorders. One of the
subcategories of reproductive system disorders to be more
represented, with P-value (calculated by Fisher’s Exact test)
of 6.1·10
−18, was endometriosis with 119 molecules directly
involved in this pathology (Table 3).
An exempliﬁcative network identiﬁed by IPA enriched
for miRNA targets involved in endometriosis is shown in
Figure 2. This network, converging on estrogen receptor 1
(ESR1), includes the DNA methyltransferases DNMT3A and
DNMT3B that are validated targets of hsa-miR-29b and
hsa-miR-29c, and of hsa-miR-29b, hsa-miR-29c, and hsa-
miR-148a, respectively [45, 46]. DNA methylation is an
epigenetic modiﬁcation that is involved in gene silencing,
chromatin remodeling, and genome stability [47]. It has
been demonstrated that DNMT1, DNMT3A, and DNMT3B
are disregulated in endometriosis [48], and it has been
suggested that aberrant methylation of HOXA10 and of
the progesterone receptor PR-B may be responsible of the
disregulation of their expression in endometriosis. Thus, this
network strongly suggests a possible involvement of miRNAs
in these mechanisms.Journal of Biomedicine and Biotechnology 17
Table 3: Molecules directly involved in endometriosis and networks in which they appear. IPA analysis indicated that several networks
constituted by the predicted targets of the diﬀerentially expressed miRNAs include molecules known to be involved in endometriosis.
Symbol Entrez Gene Name Networks
Cytokines
CD40LG CD40 ligand 38
CX3CL1 chemokine (C-X3-C motif) ligand 1 12
CXCL13 chemokine (C-X-C motif) ligand 13 36
IL2 interleukin 2 2, 29, 37
IL4 interleukin 4 29, 32, 37
IL6 interleukin 6 (interferon, beta 2) 29
IL8 interleukin 8 28, 31
IL18 interleukin 18
(interferon-gamma-inducing factor)
29
SPP1 secreted phosphoprotein 1 23, 46
TNF t u m o rn e c r o s i sf a c t o r( T N F
superfamily, member 2)
26, 29, 30,
33, 37, 38,
40, 41, 45
Enzymes
CNTN1 contactin 1 23
DNMT1 DNA (cytosine-5-)-methyltransferase
1
5, 36
DNMT3A DNA (cytosine-5-)-methyltransferase
3a l p h a
5
DNMT3B DNA (cytosine-5-)-methyltransferase
3b e t a
5
FN1 ﬁbronectin 1 7, 28
GNAS GNAS complex locus 41
GSTP1 glutathione S-transferase pi 1 49
HINT1 histidine triad nucleotide binding
protein 1
48
KRAS v-Ki-ras2 Kirsten rat sarcoma viral
oncogene homolog
3
PDE4A
phosphodiesterase 4A, cAMP-speciﬁc
(phosphodiesterase E2 dunce
homolog, Drosophila)
44
PDE4D
phosphodiesterase 4D, cAMP-speciﬁc
(phosphodiesterase E3 dunce
homolog, Drosophila)
41
PTGS2
prostaglandin-endoperoxide synthase
2 (prostaglandin G/H synthase and
cyclooxygenase)
7, 28
RAC1
ras-related C3 botulinum toxin
substrate 1 (rho family, small GTP
binding protein Rac1)
5
RAP1B RAP1B, member of RAS oncogene
family
23
REV3L REV3-like, catalytic subunit of DNA
polymerase zeta (yeast)
39
RRM1 (includes EG:6240) ribonucleotide reductase M1 26
SAT1 spermidine/spermine
N1-acetyltransferase 1
26
XRCC6 X-ray repair complementing defective
repair in Chinese hamster cells 6
42, 4818 Journal of Biomedicine and Biotechnology
Table 3: Continued.
Symbol Entrez Gene Name Networks
Growth Factors
ANGPT2 angiopoietin 2 7
CTGF connective tissue growth factor 2, 36, 40
FGF2 ﬁbroblast growth factor 2 (basic) 23, 31
INHBA inhibin, beta A 45
LEP leptin 6
TGFB1 transforming growth factor, beta 1
20, 26, 33,
35, 40, 45
VEGFA vascular endothelial growth factor A 29, 30
Ion Channels PKD1 polycystic kidney disease 1 (autosomal
dominant)
45
PKD2 (includes EG:5311) polycystic kidney disease 2 (autosomal
dominant)
45
Kinases
CDC2 c e l ld i v i s i o nc y c l e2 ,G 1t oSa n dG 2t o
M
32, 36
CSF1R colony stimulating factor 1 receptor 3, 34
EGFR
e p i d e r m a lg r o w t hf a c t o rr e c e p t o r
(erythroblastic leukemia viral
(v-erb-b) oncogene homolog, avian)
28
ERBB2
v-erb-b2 erythroblastic leukemia viral
oncogene homolog 2,
neuro/glioblastoma derived oncogene
homolog (avian)
27, 30, 33,
35, 38, 40,
45, 47
FLT1
fms-related tyrosine kinase 1 (vascular
endothelial growth factor/vascular
permeability factor receptor)
2
INSR insulin receptor 26
JAK1 Janus kinase 1 (a protein tyrosine
kinase)
37
KIT v-kit Hardy-Zuckerman 4 feline
sarcoma viral oncogene homolog
9
MAPK4 mitogen-activated protein kinase 4 17
NTRK2 neurotrophic tyrosine kinase, receptor,
type 2
45
PCK1 phosphoenolpyruvate carboxykinase 1
(soluble)
42
PDGFRA platelet-derived growth factor
receptor, alpha polypeptide
11
PDGFRB platelet-derived growth factor
receptor, beta polypeptide
11
PIK3R2 phosphoinositide-3-kinase, regulatory
subunit 2 (beta)
17
SGK1 serum/glucocorticoid regulated kinase
1
16
STC1 stanniocalcin 1 49
WEE1 WEE1 homolog (S. pombe) 18
Ligand-Dependent
Nuclear Receptors
AHR aryl hydrocarbon receptor 44
AR androgen receptor 30
ESR1 estrogen receptor 1 5, 30, 44
ESR2 estrogen receptor 2 (ER beta) 44Journal of Biomedicine and Biotechnology 19
Table 3: Continued.
Symbol Entrez Gene Name Networks
PPARG peroxisome proliferator-activated
receptor gamma 12, 29
Peptidases
HPR (includes EG:3250) haptoglobin-related protein 24
MEST mesoderm speciﬁc transcript homolog
(mouse) 18
MMP2
matrix metallopeptidase 2 (gelatinase
A, 72kDa gelatinase, 72kDa type IV
collagenase)
11
Phosphatases
DUSP1 dual speciﬁcity phosphatase 1 3
PPP3R1 protein phosphatase 3 (formerly 2B),
regulatory subunit B, alpha isoform 24
PTEN phosphatase and tensin homolog 19
PTP4A1 protein tyrosine phosphatase type IVA,
member 1 22
Transcription
Regulators
BCL6 B-cell CLL/lymphoma 6 16
BRCA1 breast cancer 1, early onset 5, 30, 42
CITED2
Cbp/p300-interacting transactivator,
with Glu/Asp-rich carboxy-terminal
domain, 2
11
CREB1 cAMP responsive element binding
protein 1 6
EGR1 early growth response 1 6, 26, 35
EMX2 empty spiracles homeobox 2 15
FOS v-fos FBJ murine osteosarcoma viral
oncogene homolog 6, 35, 49
FOXO1 forkhead box O1 3
GATA3 GATA binding protein 3 2
HIF1A
hypoxia inducible factor 1, alpha
subunit (basic helix-loop-helix
transcription factor)
10, 31, 44,
47
ID1 inhibitor of DNA binding 1, dominant
negative helix-loop-helix protein 47, 50
JUN jun oncogene 49
JUNB jun B proto-oncogene 11, 47
NRIP1 nuclear receptor interacting protein 1 36
REL v-rel reticuloendotheliosis viral
oncogene homolog (avian) 44
SMAD6 SMAD family member 6 14
SMAD7 SMAD family member 7 11
SP2 Sp2 transcription factor 31
TP53 tumor protein p53
22, 27, 32,
34, 36, 37,
40, 41, 45
WT1 Wilms tumor 1 7
ZFP36 zinc ﬁnger protein 36, C3H type,
homolog (mouse) 20
Transmembrane
Receptors
IL2RG interleukin 2 receptor, gamma (severe
combined immunodeﬁciency) 37
ITGB1
integrin, beta 1 (ﬁbronectin receptor,
beta polypeptide, antigen CD29
includes MDF2, MSK12)
11, 28, 30
ITGB3 integrin, beta 3 (platelet glycoprotein
IIIa, antigen CD61) 720 Journal of Biomedicine and Biotechnology
Table 3: Continued.
Symbol Entrez Gene Name Networks
ITGB4 integrin, beta 4 30
Transporters
APOE apolipoprotein E 36
ATP1B1 ATPase, Na+/K+ transporting, beta 1
polypeptide 41
ATP2B2 ATPase, Ca++ transporting, plasma
membrane 2 21
SLC6A6
solute carrier family 6
(neurotransmitter transporter,
taurine), member 6
1
Others
ACTB actin, beta 9, 49
ANK3 ankyrin 3, node of Ranvier (ankyrin
G) 24
BCL2 B-cell CLL/lymphoma 2 3, 48
BIRC5 baculoviral IAP repeat-containing 5 36
BSG basigin (Ok blood group) 41
CAV2 caveolin 2 5
CCNA2 cyclin A2 43
COL18A1 collagen, type XVIII, alpha 1 47
DCN decorin 28
EPS15 e p i d e r m a lg r o w t hf a c t o rr e c e p t o r
pathway substrate 15 28
ERRFI1 ERBB receptor feedback inhibitor 1 45
EZR ezrin 18
FBN1 ﬁbrillin 1 36
IRS2 insulin receptor substrate 2 6, 37
ITGA6 integrin, alpha 6 30
LRP5 low density lipoprotein
receptor-related protein 5 6
MARCKS (includes
EG:4082)
myristoylated alanine-rich protein
kinase C substrate 47
SDC2 syndecan 2 8
TAL1 T-cell acute lymphocytic leukemia 1 18
THBS2 thrombospondin 2 11
TIMP2 TIMP metallopeptidase inhibitor 2 11
TMSB10 thymosin beta 10 19
TRAF2 TNF receptor-associated factor 2 26
VIM vimentin 19, 36
To further analyze the possible role of these diﬀeren-
tially expressed miRNAs in endometriosis, we performed a
diﬀerent analysis uploading the miRNAs directly in IPA. In
this way, the software identiﬁed 6 networks, 3 of which are
highly signiﬁcant with known biological functions including
genetic disorders, connective tissue disorders, skeletal and
muscular disorders, cancer, and reproductive system disor-
ders (Table 4).
The diﬀerence in the number of networks identiﬁed
by IPA is ascribable to the diﬀerent database used by
the software, as IPA uses the Argonaute 2 databases
(http://www.ma.uni-heidelberg.de/apps/zmf/argonaute/)t o
analyse miRNAs and their known or predicted targets, and
this database identiﬁed only 118 targets for the 50miRNAs.
Next, we performed an IPA analysis on the 1203 pre-
dicted targets of the miRNAs whose diﬀerential expression
between eutopic and ectopic tissue was conﬁrmed by real-
time RT-PCR. IPA software identiﬁed 49 networks and
revealed that the predicted targets were enriched for biologi-
cal functions such as cellular development, cell morphology,
cell-mediated immune response, gene expression, cell cycle,
celldeath,cancer,anddevelopmentaldisorders.Thenetwork
with the highest score from this analysis, shown in Figure 3,
includesmoleculesthathavebeenimplicatedinendometrio-
sis such as the TNF receptor, IL10, IL6, and FOXO1 [49–55].
Performing the analysis uploading directly the miRNAs
in IPA, thus using the Argonaute2 database, the software
identiﬁed only one network (Figure 4), the major biologicalJournal of Biomedicine and Biotechnology 21
Table 4: Molecular networks constituted by the predicted miRNA targets. The list of diﬀerentially expressed miRNAs was directly
uploaded in IPA and an analysis was performed in order to identify the molecular pathways and functions to which the predicted
targets of the diﬀerentially expressed miRNAs belong. The database used by IPA to analyze miRNAs and their targets is Argonaute2
(http://www.ma.uni-heidelberg.de/apps/zmf/argonaute/). P<. 01.
ID Molecules in Network P-value Focus
Molecules Top Functions
1
AKAP3, ATP2A2, C11ORF87, CNKSR2,
CREB1, CUGBP2, EIF4E3, ELK1, FLRT2,
HOXB2, HOXD12, IFNG, KLHDC10,
KPNB1, MIR25, MIR150, MIR186,
MIR221, MIR299, MIR143 (includes
EG:406935), MIR182 (includes
EG:406958), MIR200A, MIR200B,
MIR200C, MIR34A, MYST4, OTOF,
PAQR3, PER1, RPGRIP1L, SNRPA,
SRCAP, UBFD1, USP6NL, WDR44
10E−24 11
Genetic Disorder, Skeletal and
Muscular Disorders,
Connective Tissue Disorders
2
ATP1B1, C4ORF16, CALU, DHX15,
DIP2C, DNMT3A, DNMT3B,E V X 2 ,
FAM108C1, FBXL11, HOXA5, HOXA10,
INO80, JPH3, KLHL18, MACF1,
MAP2K6, MIR126, MIR100 (includes
EG:406892), MIR130A (includes
EG:406919), MIR130B (includes
EG:406920), MIR132 (includes
EG:406921), MIR148A (includes
EG:406940), MIR20A, MIR29B,
MIR29B1, MIR29B2, MIR29C, MPPED2
(includes EG:744), NUFIP2, SMARCE1,
SOX6, ZFP36L2, ZNF238, ZNF318
(includes EG:24149)
10E–19 9
Genetic Disorder, Skeletal and
Muscular Disorders, Infection
Mechanism
3
ADIPOR2, AR, ARF4, CAND1, CCNT2,
CDKN1A, CHSY1, FBXW7, FNDC3B,
IRS1, JUN, KLF6, LASS2, MAP1D,
MDM2, MIR93, MIR375, MIR1
(human), MIR106A (includes
EG:406899), MIR106B (includes
EG:406900), MIR145 (includes
EG:406937), MIR183 (includes
EG:406959), MIR196B, MIR99A, MTPN,
N P A T ,N P P C ,P D C D 4 ,P F T K 1 ,P P M 1 D ,
SERP1, SERPINB5, SLC16A2, TDG,
TRIM2
10E−18 9 Cancer, Reproductive System
Disease, Cell Cycle
4 MIR376A, MIR376A1, MIR376A2 10E−21 Genetic Disorder, Skeletal and
Muscular Disorders
5 MIR365, MIR365-1, MIR365-2 10E−21
6 EZH2, MIR101, MIR101-1, MIR101-2,
MYCN 10E−21 Cancer, Cellular Movement,
Reproductive System Disease
functions of which are cell cycle, cell death, and connective
tissue disorders. This network contains PIK3R1, and its
expression has been demonstrated to be upregulated in
endometriosis, were it can play an essential role in TNF-
mediated antiapoptotic signaling [56]. Another interesting
molecule present in this pathway is SIP1, a validated target of
the miR-200 family, which is a factor implicated in epithelial
to mesenchymal transition and tumor metastasis [57]. Thus,
the observed downregulation of miR-200 family in the
ectopic endometrium may have a role in the endometrial
lesion development.
We further investigated the function of the predicted
targets of the RT-PCR-validated miRNAs by using Onto-
Express and Pathway-Express (http://vortex.cs.wayne.edu/)
inordertocategorizethetargetsaccordingtoGeneOntology
(GO) and KEGG pathways, respectively [58, 59]. The
predicted targets of the validated miRNAs were uploaded
in Onto-Express and the list of the putative targets of
the 475miRNAs assayed was used as reference. Onto-
Express calculates the mRNA targets in each GO category
and compares it with the expected number of targets
present in the GO category. Signiﬁcant diﬀerences from22 Journal of Biomedicine and Biotechnology
Table 5: Gene Ontology analysis of the predicted target genes of 50miRNAs diﬀerentially expressed. Onto-Express analysis on predicted
targets of the diﬀerentially expressed miRNAs identiﬁed enrichment for biological process categories. The gene column indicates the number
ofpredictedtargetsofthediﬀerentiallyexpressedmiRNAsuponthenumberofthetargetsofallmiRNAsconsideredforthestudy.Signiﬁcant
diﬀerences from the number of targets in each GO category with the expected number of genes were calculated with the assumption of a
hypergeometric distribution and P-values were adjusted with the false discovery rate (fdr) correction. P<. 05.
Rank Biological process category Genes
Corrected
P-value
1 Cellular process 2408/6644 .0
Cell motion 148/330 .0
Cell communication 908/2223 .0
Cellular component organization 546/1383 .0
Cellular developmental process 400/949 .0
Cellular metabolic process 1563/4269 .0
Regulation of cellular process 1555/3840 .0
Cell development 183/419 .0
Positive regulation of cellular process 371/875 .0
Negative regulation of cellular process 394/932 .0
Cell cycle 223/555 1.0E−5
Cell death 235/587 2.0E−5
Cell proliferation 237/602 5.0E−5
Actin-ﬁlament based process 90/197 6.0E−5
Cell fate commitment 45/83 9.0E−5
Cell aging 14/21 7.0E−4
Vescicle-mediated transport 158/397 7.3E−4
Cell growth 51/112 .00286
Cell fate determination 15/23 .00286
Cellular localization 224/609 .00506
Gene silencing 16/27 .00696
Cell cycle process 124/323 .00696
Translational initiation 23/48 .01253
Cell fate speciﬁcation 12/20 .01728
Cellular response to stimulus 110/292 .03290
Cell adhesion 173/479 .04094
2 Negative regulation of biological process 421/992 .0
Negative regulation of metabolic process 193/422 .0
Negative regulation to cellular process 394/932 .0
Negative regulation of developmental process 129/309 1.9E−4
Negative regulation of response to stimulus 16/29 .01705
Negative regulation of growth 24/53 .03564
3 Multicellular organismal process 820/2037 .0
Multicellular organismal development 675/1606 .0
Regulation of multicellular organismal process 171/421 2.0E−4
System process 227/606 .00750
Respiratory gaseous exchange 11/17 .01639
4 Biological regulation 1656/4148 .0
Regulation of molecular function 211/478 .0
Regulation of biological process 1597/3961 .0
Regulation of biological quality 281/732 1.3E−4Journal of Biomedicine and Biotechnology 23
Table 5: Continued.
Rank Biological process category Genes
Corrected
P-value
5 Regulation of biological process 1597/3961 .0
Regulation of metabolic process 850/2038 .0
Regulation of developmental process 283/657 .0
Regulation of cellular process 1555/3840 .0
Positive regulation of cellular process 384/933 .0
Negative regulation of cellular process 421/992 .0
Regulation of multicellular organismal process 171/421 1.4E−4
Regulation of localization 110/261 8.7E−4
Regulation of locomotion 41/95 .02619
Regulation of growth 64/164 .04199
6 Metabolic process 1631/4509 .0
Biosynthetic process 899/2354 .0
Negative regulation of metabolic process 193/422 .0
Positive regulation of metabolic process 201/473 .0
Regulation of metabolic process 1563/2038 .0
Cellular metabolic process 1563/4269 .0
Primary metabolic process 1551/4187 .0
Macromolecule metabolic process 1383/3644 .0
Oxydation reduction 52/255 5.0E−5
Catabolic process 237/665 .01317
Nitrogen compound metabolic process 49/193 .03270
7 Developmental process 821/1967 .0
Multicellular organismal development 675/1606 .0
Anatomical structure morphogenesis 310/710 .0
Embryonic development 140/304 .0
Anatomical structure development 584/1379 .0
Cellular developmental process 400/949 .0
Regulation of developmental process 283/657 .0
Positive regulation of developmental process 131/295 1.0E−5
Anatomical structure formation involved in Morphogenesis 97/216 4.0E−5
Pattern speciﬁcation process 79/173 1.6E−4
Negative regulation of developmental process 129/309 1.6E−4
Pigmentation during development 9/13 .01264
Reproductive developmental process 31/68 .02708
Aging 17/36 .04082
8 Positive regulation of biological process 384/933 .0
Positive regulation of metabolic process 201/473 .0
Positive regulation of cellular process 371/875 .0
Positive regulation of developmental process 131/295 1.0E−5
Positive regulation of homeostatic process 6/8 .03203
9 Localization 715/1953 .0
Localization of cell 148/330 .0
Macromolecule localization 247/638 1.1E−4
Regulation of localization 110/261 7.7E−4
Cellular localization 224/609 .00422
Establishment of localization 577/1657 .0046324 Journal of Biomedicine and Biotechnology
Table 5: Continued.
Rank Biological process category Genes Corrected
P-value
10 Death 235/591 2.0E−5
Cell death 235/587 1.0E−5
11 Anatomical structure formation 242/629 1.1E−4
Anatomical structure formation involved in Morphogenesis 97/216 3.0E−5
Cellular component assembly 165/452 .01276
12 Response to stimulus 464/1276 2.4E−4
Response to chemical stimulus 185/465 5.3E−4
Response to endogenous stimulus 59/136 .00633
Negative regulation to response to stimulus 16/29 .01844
Behavior 84/215 .02638
Cellular response to stimulus 110/292 .03534
Response to stress 253/718 .03918
13 Multi-organism process 113/286 .00251
Interspecies interaction between organisms 71/172 .00565
Female pregnancy 19/39 .04504
14 Growth 96/235 .00334
Cell growth 51/112 .00298
Negative regulation of growth 24/53 .03391
Regulation of growth 64/164 .03916
15 Locomotion 111/277 .00422
Cell motility 97/223 3.5E−4
Regulation of locomotion 41/95 .02439
16 Establishment of localization 577/1657 .00458
Establishment of protein localization 207/536 3.3E−4
Establishment of localization in cell 209/576 .01045
17 Reproduction 117/303 .00983
Reproductive process 116/301 .01127
18 Reproductive process 116/301 .01024
Reproductive developmental process 31/68 .03090
Female pregnancy 19/39 .04504
19 Biological adhesion 173/479 .03486
Cell adhesion 173/479 .03486
20 Rhythmic process 26/59 .04158
the expected number of genes were calculated assuming a
hypergeometric distribution, and P values were adjusted
with the false discovery rate correction based on the
number of GO categories tested. A corrected P value <
.05 was considered statistically signiﬁcant. Onto-Express
analysis revealed enrichment for several biological processes
known to be relevant in endometriosis, such as develop-
mental process, cell death, cell cycle, and cell adhesion
(Table 5).
Pathway-Express analysis identiﬁed 33 pathways signif-
icant at 5% level (Table 6), most of which are coherent
with the current knowledge on endometriosis. For instance,
the most signiﬁcant pathways putatively aﬀected by the
diﬀerential expression of miRNAs are MAPK and axon
guidance the latter shown in Figure 5. While MAPK pathway,
which is involved in several cellular functions, such as
cell proliferation, migration, and diﬀerentiation, is clearly
relevant for endometriosis, axon guidance,a tﬁ r s tm a y
appear unrelated to this pathology. However, nerves and
blood vessels are highly interconnected, both physically and
in their morphogenesis. Indeed, it has been demonstrated
that several molecules involved in axon guidance, such as
semaphorins, plexins, and neuropilins, are also strongly
implicated in angiogenesis [60], a biological process essen-
tial for endometriosis. Intriguingly, this pathway contains
ROBO1, and its expression, higher in ectopic endometrium
compared to eutopic tissue, positively correlates with
endometriosis recurrence [61], thus suggesting that miRNAs
may take part in tuning ROBO1 expression and have a role
in the recurrence of the pathology.Journal of Biomedicine and Biotechnology 25
Table 6: KEGG pathways containing the predicted targets of the diﬀerentially expressed miRNAs. Pathway-Express analysis identiﬁed the
KEGG molecular pathways aﬀected by the predicted targets of the diﬀerentially expressed miRNAs. P<. 05.
Rank Pathway name Genes in pathway Input genes in pathway Pathway genes on chip P-value
1 MAPK signaling pathway 272 103 197 3.23E−08
2 Axon guidance 129 67 113 3.23E−08
3 Melanogenesis 102 48 74 8.60E−08
4 Pathways in cancer 330 119 245 2.27E−07
5 Regulation of actin cytoskeleton 217 78 158 2.31E−05
6 Focal adhesion 203 75 150 2.31E−05
7 Wnt signaling pathway 152 63 127 1.60E−04
8 Glioma 65 30 50 2.94E−04
9 GnRH signaling pathway 103 36 65 4.86E−04
10 Renal cell carcinoma 69 34 61 5.92E−04
11 Insulin signaling pathway 138 49 98 7.02E−04
12 Adherens junction 78 34 62 7.65E−04
13 TGF-beta signaling pathway 87 38 72 8.49E−04
14 Prostate cancer 90 36 68 .0011
15 ECM-receptor interaction 84 30 55 .0016
16 Phosphatidylinositol signaling system 76 30 55 .0016
17 Calcium signaling pathway 182 54 115 .0016
18 Colorectal cancer 84 36 70 .0018
19 Long-term potentiation 73 31 58 .0018
20 Adipocytokine signaling pathway 67 27 50 .0032
21 ErbB signaling pathway 87 34 69 .0056
22 Pancreatic cancer 72 30 59 .0056
23 Gap junction 96 33 67 .0063
24 Type II diabetes mellitus 45 18 31 .0069
25 Small cell lung cancer 86 30 61 .0095
26 Thyroid cancer 29 14 23 .0111
27 Ubiquitin mediated proteolysis 138 42 94 .0145
28 Long-term depression 75 24 49 .0225
29 Non-small cell lung cancer 54 20 39 .0225
30 Acute myeloid leukemia 59 22 45 .0304
31 Melanoma 71 25 53 .0323
32 Cardiac muscle contraction 87 20 41 .0402
33 Chronic myeloid leukemia 75 28 62 .0410
3.4. Genes Diﬀerentially Expressed in Endometriosis Are
Predicted Targets of the Diﬀerentially Expressed miRNAs.
Finally, after the identiﬁcation of the predicted targets of
thediﬀerentiallyexpressed miRNAs, we investigated whether
they were in accordance with the results of two studies of
geneexpressionin endometriosis. Weﬁrst analysedthe genes
reported to be diﬀerentially expressed in a study on paired
eutopic and ectopic samples of ovarian endometriosis [23].
This study identiﬁed 701 diﬀerentially expressed transcripts
(expression ≥ 0.2; fold change ±≥2; P ≤ .05), 82 of
which are predicted target genes of the 50 miRNAs, 51/492
upregulated and 31/209 downregulated. A second study on
peritoneal endometriosis [24] identiﬁed 622 diﬀerentially
expressed transcripts (fold change ±≥1.5; P ≤ .05), 107
of which are predicted targets of the diﬀerentially expressed
miRNAs, 73/232 upregulated and 34/390 downregulated.
Hypothesising that the genes diﬀerentially expressed com-
mon to both studies are likely those speciﬁc to endometriosis
independently from the site of the lesion, we restricted
the analysis to the diﬀerentially regulated genes in eutopic
and ectopic endometrium common to the two studies that
are also predicted targets of the 50miRNAs (Table 7). IPA
analysis identiﬁed 5 molecular networks, the most relevant
functions of which being cancer, cell cycle, and reproductive
system disease (Table 8). The overlap of networks generated
by IPA is shown in Figure 6. In this graphical representation
the most relevant nodes are the transcription factor SP1,
tumor necrosis factor (TNF), and SRC, in remarkable
agreement with the nodes of the most signiﬁcant networks
obtained by IPA analysis performed on the distinct datasets
of diﬀerentially expressed genes in ovarian and peritoneal
endometriosis (data not shown).26 Journal of Biomedicine and Biotechnology
Table 7: Genes aberrantly expressed in ovarian and peritoneal endometriosis that are predicted targets of the diﬀerentially expressed
miRNAs.ThemiRNAspredictedtoregulatetheexpressionofthegenesknowntobeaberrantlyup-(↑)ordownregulated(↓)inbotho varian
andperitonealendometriosiswereidentiﬁedbyTARGETSCANandPICTARalgorithms.MicroRNAswhoseregulationisinaccordancewith
the resulting expression of their predicted target genes are reported in bold.
Target genes microRNAs upregulated microRNAs downregulated
CA3 (carbonic anhydrase III) ↑ hsa-miR-29b; hsa-miR-29c
CAV1 (caveolin 1) ↑ hsa-miR-199a; hsa-miR-30e-3p hsa-miR-20a;hsa-miR-106b
CAV2 (caveolin 2) ↑ hsa-miR-29b; hsa-miR-29c
DMD (dystrophin) ↑ hsa-miR-101; hsa-miR-30e-5p hsa-miR-200b;hsa-miR-200c
EPHA3 (EPH receptor A3) ↑ hsa-miR-29b; hsa-miR-29c hsa-miR-182
FZD7 ↑ (frizzled homolog 7) hsa-miR-145; hsa-miR-1 hsa-miR-20a;hsa-miR-106b
GALNT3
(UDP-N-acetyl-alpha-D-galactosamine) ↓ hsa-miR-30e-5p
KCNMA1 (potassium large conductance
calcium-activated channel, subfamily M,
alpha mamber 1) ↑
hsa-miR-186 hsa-miR-93;hsa-miR-17-5p;
hsa-miR-20a;hsa-miR-106b
LMO3 (LIM domain only 3) ↑
hsa-miR-20a;hsa-miR-93;
hsa-miR-17-5p;hsa-miR-183;
hsa-miR-106b
NFASC (neurofascin) ↑ hsa-miR-150 hsa-miR-200b;hsa-miR-200c;
hsa-miR-182
PDE4DIP (phosphodiesterase 4D interacting
protein) ↑ hsa-miR-183
PLS1 (plastin 1) ↓ hsa-miR-30e-5p hsa-miR-17-5p; hsa-miR-20a;
hsa-miR-106b
PTPN3 (protein tyrosine phosphatase,
non-receptor type 3) ↓
hsa-miR-17-5p; hsa-miR-20a;
hsa-miR-106b
RGS2 (regulator of G-protein signalling 2) ↑ hsa-miR-30e-5p hsa-miR-182
RGS5 (regulator of G-protein signalling 5) ↑ hsa-miR-186
RPS6KA5 (ribosomal protein S6 kinase,
90kDa, polypeptide 5) ↓ hsa-miR-148a hsa-miR-93; hsa-miR-17-5p;
hsa-miR-20a; hsa-miR-106b
SCAP2 (src family associated phosphoprotein
2) ↑ hsa-miR-182
SLCO3A1 (solute carrier organic anion
transporter family, member 3A1) ↑ hsa-miR-34a hsa-miR-182
SNAP25 (synaptosomal-associated protein) ↑ hsa-miR-130a; hsa-miR-1 hsa-miR-130b;hsa-miR-200b;
hsa-miR-200c
TNFSF12 (tumor necrosis factor superfamily,
member 12) ↑ hsa-miR-28
4. Conclusions
MicroRNAs are predicted to regulate a large fraction of
protein-coding genes, as computational analysis reveals that
an average miRNA could have as many as 100 or more target
genes. On the other hand, a single gene may have target sites
for several distinct miRNAs, allowing a ﬁne tuning of gene
expression by miRNAs.
Inthepresentstudy,weusedmiRNAmicroarraytechnol-
ogy to identify the miRNAs diﬀerentially expressed in paired
eutopic/ectopic endometrium from the same patients and
bioinformatics tools to identify their predicted targets as well
as the molecular networks and the biological functions they
may aﬀect.
Comparing miRNA expression proﬁles among the diﬀer-
entsubjects,weidentiﬁed50miRNAsdiﬀerentiallyexpressed
in ectopic versus eutopic samples. Several of these miRNAs
were also reported to be diﬀerentially expressed in two
recent studies [62, 63], although with a modulation occa-
sionally discordant from our results. This, joint to a notable
accordance between their predicted targets and the genes
reported to be diﬀerentially expressed in two studies of gene
expression [23, 24], consolidates the hypothesis of a possible
role of miRNAs in the pathogenesis of endometriosis.
The miRNAs-predicted targets were identiﬁed by the
intersection of the results from two diﬀerent search
algorithms, and the biological functions the diﬀerentially
expressed miRNA may aﬀect were identiﬁed by Onto-
Express and IPA software. Functional analysis, performed
using IPA software, was carried out uploading either the
predictedtargetsorthediﬀerentiallyexpressedmiRNAs,thus
using diﬀerent databases for miRNA targets. As expected,Journal of Biomedicine and Biotechnology 27
Table 8: Molecular networks constituted by the common diﬀerentially expressed transcripts in ovarian and peritoneal endometriosis
predicted to be targets of the 50 miRNAs. Diﬀerentially expressed genes common to both ovarian and peritoneal endometriosis that are
predicted targets of the 50 diﬀerentially expressed miRNAs were uploaded in IPA in order to identify the molecular networks and functions
to which they belong. P<. 01.
ID Molecules in Network P-value Focus
Molecules Top Functions
1
CAV1, CAV2, CDKN1A, ESR1,
HMGA1, LPL, MMP2, NOS3,
SMARCA4, SP1, SP3, SRC,
TNFSF12, TP53
10E−84 C a n c e r ,C e l lC y c l e ,R e p r o d u c t i v e
System Disease
2 MBD1, SLCO3A1 10E−21
Lipid Metabolism, Molecular
Transport, Small Molecule
Biochemistry
3 RGS2, TNF 10E−21
Lipid Metabolism, Small
Molecule Biochemistry, Cell
Signaling
4 DMD, DTNA, DTNB 10E−21
Cellular Assembly and
Organization, Nervous System
Development and Function,
Skeletal and Muscular System
Development and Function
5 FYB, GRB2, SKAP2 10E−21
Cell-To-Cell Signaling and
Interaction, Cell-mediated
Immune Response, Cellular
Growth and Proliferation
the diﬀerent algorithms used to predict miRNA targets led
to the identiﬁcation of diﬀerent molecular networks. Still,
in both cases, the identiﬁed networks contained several
transcripts known to be implicated in endometriosis and
with their main biological functions linked to the disease.
Since the targets of miRNAs are just predictions based on
mathematical algorithms, the choice of the algorithm may
radically modify on the whole the list of the predicted target
genes and that of the molecular networks they belong to. For
this reason, the validation of miRNA targets in vitro, in a
cellular system, is essential to evaluate the contribution of
each miRNA to the overall modulation of gene expression.
Acknowledgments
The authors gratefully acknowledge Flavia Prodam for
assistance with statistical analysis, Francesca Riboni for
skilled help in collecting samples, Paolo Borasio and Chiara
Airoldi for the assistance in databases analysis, and Michele
Ferrara for his valuable help in preparing this manuscript. N.
FilighedduandI.Gregnanincontributedequallytothiswork
References
[1] R. F. Kruitwagen, L. G. Poels, W. N. P. Willemsen, I. J. Y. de
Ronde, P. H. K. Jap, and R. Rolland, “Endometrial epithelial
cells in peritoneal ﬂuid during the early follicular phase,”
Fertility and Sterility, vol. 55, no. 2, pp. 297–303, 1991.
[ 2 ]W .P .D m o w s k i ,R .W .S t e e l e ,a n dG .F .B a k e r ,“ D e ﬁ c i e n t
cellular immunity in endometriosis,” American Journal of
Obstetrics and Gynecology, vol. 141, no. 4, pp. 377–383, 1981.
[ 3 ]S .M .G i l m o r e ,S .A k s e l ,C .H o ﬀ,a n dR .D .A .P e t e r s o n ,“ I n
vitro lymphocyte activity in women with endometriosis—an
altered immune response?” Fertility and Sterility, vol. 58, no.
6, pp. 1148–1152, 1992.
[ 4 ]S .Z .A .B a d a w y ,V .C u e n c a ,H .F r e l i e c h ,a n dC .S t e f a n u ,
“Endometrial antibodies in serum and peritoneal ﬂuid of
infertile patients with and without endometriosis,” Fertility
and Sterility, vol. 53, no. 5, pp. 930–932, 1990.
[5] P. V. Taylor, M. D. Maloney, J. M. Campbell, et al., “Autore-
activity in women with endometriosis,” British Journal of
Obstetrics and Gynaecology, vol. 98, no. 7, pp. 680–684, 1991.
[6] A. F. Haney, J. J. Muscato, and J. B. Weinberg, “Peritoneal ﬂuid
cell populations in infertility patients,” Fertility and Sterility,
vol. 35, no. 6, pp. 696–698, 1981.
[ 7 ] L .V a nL e ,S . - T .O h ,J .A .A n n e r s ,C .A .R i n e h a rt ,a n dJ .H a l m e ,
“Interleukin-1 inhibits growth of normal human endometrial
stromal cells,” Obstetrics and Gynecology,v o l .8 0 ,n o .3 ,p p .
405–409, 1992.
[ 8 ]D .S e m e r ,K .R e i s l e r ,P .C .M a c D o n a l d ,a n dM .L .C a s e y ,
“Responsiveness of human endometrial stromal cells to
cytokines,” Annals of the New York Academy of Sciences, vol.
622, pp. 99–110, 1991.
[9] N. Rana, D. P. Braun, R. House, H. Gebel, C. Rotman, and
W. P. Dmowski, “Basal and stimulated secretion of cytokines
by peritoneal macrophages in women with endometriosis,”
Fertility and Sterility, vol. 65, no. 5, pp. 925–930, 1996.
[10] S. E. Rier, A. K. Parsons, and J. L. Becker, “Altered interleukin-
6 production by peritoneal leukocytes from patients with
endometriosis,” Fertility and Sterility, vol. 61, no. 2, pp. 294–
299, 1994.
[11] I. E. Sasson and H. S. Taylor, “Stem cells and the pathogenesis
of endometriosis,” Annals of the New York Academy of Sciences,
vol. 1127, pp. 106–115, 2008.28 Journal of Biomedicine and Biotechnology
[12] S. Kennedy, R. Hadﬁeld, C. Westbrook, D. E. Weeks, D.
Barlow, and S. Golding, “Magnetic resonance imaging to
assess familial risk in relatives of women with endometriosis,”
The Lancet, vol. 352, no. 9138, pp. 1440–1441, 1998.
[13] J. L. Simpson, S. Elias, L. R. Malinak, and V. C. Buttram
Jr., “Heritable aspects of endometriosis. I. Genetic studies,”
American Journal of Obstetrics and Gynecology, vol. 137, no.
3, pp. 327–331, 1980.
[14] D. Coxhead and E. J. Thomas, “Familial inheritance of
endometriosis in a British population. A case control study,”
Journal of Obstetrics and Gynaecology, vol. 13, no. 1, pp. 42–
44, 1993.
[15] M. H. Moen and P. Magnus, “The familial risk of endometrio-
sis,” Acta Obstetricia et Gynecologica Scandinavica, vol. 72, no.
7, pp. 560–564, 1993.
[16] S. Kennedy, R. Hadﬁeld, H. Mardon, and D. Barlow, “Age of
onset of pain symptoms in non-twin sisters concordant for
endometriosis,” Human Reproduction, vol. 11, no. 2, pp. 403–
405, 1996.
[17] S.Kennedy,“Thegeneticsofendometriosis,”EuropeanJournal
of Obstetrics Gynecology and Reproductive Biology, vol. 82, no.
2, pp. 129–133, 1999.
[18] S. Kennedy, S. Bennett, and D. E. Weeks, “Aﬀected sib-pair
analysis in endometriosis,” Human Reproduction Update, vol.
7, no. 4, pp. 411–418, 2001.
[19] J. Meola, J. C. Rosa e Silva, D. B. Dentillo, et al., “Diﬀerentially
expressed genes in eutopic and ectopic endometrium of
women with endometriosis,” 2009, Fertility and Sterility.
[Epub ahead of print].
[ 2 0 ]H .H o n d a ,F .F .B a r r u e t o ,J .G o g u s e v ,D .D .I m ,a n dP .J .
Morin, “Serial analysis of gene expression reveals diﬀerential
expression between endometriosis and normal endometrium.
Possible roles for AXL and SHC1 in the pathogenesis of
endometriosis,” Reproductive Biology and Endocrinology, vol.
6, article 59, 2008.
[21] W.-P. Hu, S. K. Tay, and Y. Zhao, “Endometriosis-speciﬁc
genes identiﬁed by real-time reverse transcription-polymerase
chain reaction expression proﬁling of endometriosis ver-
sus autologous uterine endometrium,” Journal of Clinical
Endocrinology and Metabolism, vol. 91, no. 1, pp. 228–238,
2006.
[22] Y. Wu, A. Kajdacsy-Balla, E. Strawn, et al., “Transcriptional
characterizations of diﬀerences between eutopic and ectopic
endometrium,” Endocrinology, vol. 147, no. 1, pp. 232–246,
2006.
[23] K. M. Eyster, O. Klinkova, V. Kennedy, and K. A. Hansen,
“Whole genome deoxyribonucleic acid microarray analysis
of gene expression in ectopic versus eutopic endometrium,”
Fertility and Sterility, vol. 88, no. 6, pp. 1505–1533, 2007.
[24] M. L. Hull, C. R. Escareno, J. M. Godsland, et al.,
“Endometrial-peritoneal interactions during endometriotic
lesion establishment,” American Journal of Pathology, vol. 173,
no. 3, pp. 700–715, 2008.
[25] R. C. Lee, R. L. Feinbaum, and V. Ambros, “The C. elegance
heterochronic gene lin-4 encodes small RNAs with antisense
complementarity to lin-14,” Cell, vol. 75, pp. 843–854, 1993.
[26] E. C. Lai, P. Tomancak, R. W. Williams, and G. M. Rubin,
“Computational identiﬁcation of Drosophila microRNA
genes,” Genome Biology, vol. 4, no. 7, article R42, 2003.
[27] L. P. Lim, N. C. Lau, E. G. Weinstein, et al., “The microRNAs
of Caenorhabditis elegans,” Genes and Development, vol. 17,
no. 8, pp. 991–1008, 2003.
[28] L. P. Lim, N. C. Lau, P. Garrett-Engele, et al., “Microarray
analysis shows that some microRNAs downregulate large
numbers of-target mRNAs,” Nature, vol. 433, no. 7027, pp.
769–773, 2005.
[29] B. P. Lewis, C. B. Burge, and D. P. Bartel, “Conserved seed
pairing, often ﬂanked by adenosines, indicates that thousands
of human genes are microRNA targets,” Cell, vol. 120, no. 1,
pp. 15–20, 2005.
[30] P. Xu, S. Y. Vernooy, M. Guo, and B. A. Hay, “The Drosophila
microRNA mir-14 suppresses cell death and is required for
normal fat metabolism,” Current Biology,v o l .1 3 ,n o .9 ,p p .
790–795, 2003.
[31] J. Brennecke, D. R. Hipfner, A. Stark, R. B. Russell, and
S. M. Cohen, “bantam encodes a developmentally regulated
microRNA that controls cell proliferation and regulates the
proapoptotic gene hid in Drosophila,” Cell, vol. 113, no. 1, pp.
25–36, 2003.
[32] J.Dostie,Z.Mourelatos,M.Yang,A.Sharma,andG.Dreyfuss,
“Numerous microRNPs in neuronal cells containing novel
microRNAs,” RNA, vol. 9, no. 2, pp. 180–186, 2003.
[33] J.Dostie,Z.Mourelatos,M.Yang,A.Sharma,andG.Dreyfuss,
“Erratum: numerous microRNPs in neuronal cells containing
novel microRNAs,” RNA, vol. 9, no. 5, pp. 631–632, 2003.
[34] V. Ambros, “The functions of animal microRNAs,” Nature,
vol. 431, no. 7006, pp. 350–355, 2004.
[35] B. M. Engels and G. Hutvagner, “Principles and eﬀects of
microRNA-mediated post-transcriptional gene regulation,”
Oncogene, vol. 25, no. 46, pp. 6163–6169, 2006.
[36] M. Jovanovic and M. O. Hengartner, “miRNAs and apoptosis:
RNAs to die for,” Oncogene, vol. 25, no. 46, pp. 6176–6187,
2006.
[37] R. Garzon, M. Fabbri, A. Cimmino, G. A. Calin, and C. M.
Croce, “MicroRNA expression and function in cancer,” Trends
in Molecular Medicine, vol. 12, no. 12, pp. 580–587, 2006.
[38] G.A.CalinandC.M.Croce,“MicroRNAsignaturesinhuman
cancers,” Nature Reviews Cancer, vol. 6, no. 11, pp. 857–866,
2006.
[39] M. Canis, J. G. Donnez, D. S. Guzick, et al., “Revised
american society for reproductive medicine classiﬁcation of
endometriosis: 1996,” Fertility and Sterility,v o l .6 7 ,n o .5 ,p p .
817–821, 1997.
[40] X. Gao, E. Gulari, and X. Zhou, “In situ synthesis of
oligonucleotide microarrays,” Biopolymers,v o l .7 3 ,n o .5 ,p p .
579–596, 2004.
[41] Q. Zhu, A. Hong, N. Sheng, et al., “microParaﬂo biochip
for nucleic acid and protein analysis,” Methods in Molecular
Biology, vol. 382, pp. 287–312, 2007.
[42] B. M. Bolstad, R. A. Irizarry, M. Astrandand, and T. P.
Speed, “A comparison of normalization methods for high
densityoligonucleotidearraydatabasedonvarianceandbias,”
Bioinformatics, vol. 19, no. 2, pp. 185–193, 2003.
[43] W. Pan, “A comparative review of statistical methods for dis-
covering diﬀerentially expressed genes in replicated microar-
ray experiments,” Bioinformatics, vol. 18, no. 4, pp. 546–554,
2002.
[44] M. B. Eisen, P. T. Spellman, P. O. Brown, and D. Botstein,
“Cluster analysis and display of genome-wide expression
patterns,” Proceedings of the National Academy of Sciences of
the United States of America, vol. 95, no. 25, pp. 14863–14868,
1998.
[45] M. Fabbri, R. Garzon, A. Cimmino, et al., “MicroRNA-
29 family reverts aberrant methylation in lung cancer by
targeting DNA methyltransferases 3A and 3B,” Proceedings
of the National Academy of Sciences of the United States of
America, vol. 104, no. 40, pp. 15805–15810, 2007.Journal of Biomedicine and Biotechnology 29
[46] A. M. Duursma, M. Kedde, M. Schrier, C. le Sage, and R.
Agami, “miR-148 targets human DNMT3b protein coding
region,” RNA, vol. 14, no. 5, pp. 872–877, 2008.
[47] P. A. Jones and S. B. Baylin, “The epigenomics of cancer,” Cell,
vol. 128, no. 4, pp. 683–692, 2007.
[48] Y. Wu, E. Strawn, Z. Basir, G. Halverson, and S.-W. Guo,
“Aberrant expression of deoxyribonucleic acid methyltrans-
ferases DNMT1, DNMT3A, and DNMT3B in women with
endometriosis,” Fertility and Sterility, vol. 87, no. 1, pp. 24–32,
2007.
[49] A. Kharﬁ, Y. Labelle, J. Mailloux, and A. Akoum, “Deﬁcient
expression of tumor necrosis factor receptor type 2 in
the endometrium of women with endometriosis,” American
Journal of Reproductive Immunology, vol. 50, no. 1, pp. 33–40,
2003.
[50] Y. S. Antsiferova, N. Yu. Sotnikova, L. V. Posiseeva, and A.
L. Shor, “Changes in the T-helper cytokine proﬁle and in
lymphocyte activation at the systemic and local levels in
women with endometriosis,” Fertility and Sterility, vol. 84, no.
6, pp. 1705–1711, 2005.
[51] O. A. Odukoya, R. Ajjan, K. Lim, P. F. Watson, A. P. Weetman,
and I. D. Cooke, “The pattern of cytokine mRNA expression
in ovarian endometriomata,” Molecular Human Reproduction,
vol. 3, no. 5, pp. 393–397, 1997.
[52] T. Tsudo, T. Harada, T. Iwabe, et al., “Altered gene expression
and secretion of interleukin-6 in stromal cells derived from
endometriotic tissues,” Fertility and Sterility,v o l .7 3 ,n o .2 ,p p .
205–211, 2000.
[53] C. M. Kyama, L. Overbergh, S. Debrock, et al., “Increased
peritoneal and endometrial gene expression of biologically
relevant cytokines and growth factors during the menstrual
phase in women with endometriosis,” Fertility and Sterility,
vol. 85, no. 6, pp. 1667–1675, 2006.
[ 5 4 ] R .O .B u r n e y ,S .T a l b i ,A .E .H a m i l t o n ,e ta l . ,“ G e n ee x p r e s s i o n
analysis of endometrium reveals progesterone resistance and
candidate susceptibility genes in women with endometriosis,”
Endocrinology, vol. 148, no. 8, pp. 3814–3826, 2007.
[55] K. Shazand, S. Baban, C. Prive, et al., “FOXO1 and c-jun
transcription factors mRNA are modulated in endometriosis,”
Molecular Human Reproduction, vol. 10, no. 12, pp. 871–877,
2004.
[56] S. Matsuzaki, M. Canis, C. Vaurs-Barri` ere, O. Boespﬂug-
Tanguy, B. Dastugue, and G. Mage, “DNA microarray analysis
of gene expression in eutopic endometrium from patients
with deep endometriosis using laser capture microdissection,”
Fertility and Sterility, vol. 84, supplement 2, pp. 1180–1190,
2005.
[ 5 7 ]P .A .G r e g o r y ,A .G .B e r t ,E .L .P a t e r s o n ,e ta l . ,“ T h em i R -
200 family and miR-205 regulate epithelial to mesenchymal
transition by targeting ZEB1 and SIP1,” Nature Cell Biology,
vol. 10, no. 5, pp. 593–601, 2008.
[58] P. Khatri, P. Bhavsar, G. Bawa, and S. Draghici, “Onto-tools:
an ensemble of web-accessible ontology-based tools for the
functional design and interpretation of high-throughput gene
expression experiments,” Nucleic Acids Research, vol. 32, pp.
W449–W456, 2004.
[59] S. Draghici, P. Khatri, A. L. Tarca, et al., “A systems biology
approachforpathwaylevelanalysis,”GenomeResearch,vol.17,
no. 10, pp. 1537–1545, 2007.
[60] Y. Zhou, R.-A. F. Gunput, and R. J. Pasterkamp, “Semaphorin
signaling: progress made and promises ahead,” Trends in
Biochemical Sciences, vol. 33, no. 4, pp. 161–170, 2008.
[61] F. Shen, X. Liu, J.-G. Geng, and S.-W. Guo, “Increased
immunoreactivity to SLIT/ROBO1 in ovarian endometri-
omas:alikelyconstituentbiomarkerforrecurrence,”American
Journal of Pathology, vol. 175, no. 2, pp. 479–488, 2009.
[62] Q. Pan, X. Luo, T. Toloubeydokhti, and N. Chegini, “The
expression proﬁle of micro-RNA in endometrium and
endometriosis and the inﬂuence of ovarian steroids on their
expression,” Molecular Human Reproduction, vol. 13, no. 11,
pp. 797–806, 2007.
[63] E. M. C. O. Teague, K. H. Van der Hoek, M. B. Van der
Hoek, et al., “MicroRNA-regulated pathways associated with
endometriosis,” Molecular Endocrinology,v o l .2 3 ,n o .2 ,p p .
265–275, 2009.